Alpha DNA Investment Management’s Evolent Health EVH Stock Holding History

Alpha DNA Investment Management’s Portfolio EVH Stock Details EVH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-16,057	Closed	-$527K	–	219
2024 Q1	$527K	Buy	+16,057	New	+$512K	0.19%	129
2023 Q2	–	Sell	-33,231	Closed	-$1.08M	–	180
2023 Q1	$1.08M	Buy	+33,231	New	+$1.05M	0.32%	84
2022 Q1	–	Sell	-57,161	Closed	-$1.58M	–	130
2021 Q4	$1.58M	Buy	+57,161	New	+$1.64M	1%	44
2021 Q2	–	Sell	-332	Closed	-$6K	–	273
2021 Q1	$6K	Hold	332	–	–	0.01%	332
2020 Q4	$5K	Buy	+332	New	+$4.39K	0.01%	364

Other funds holding EVH

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Engaged Capital Newport Beach, California $303M AUM 2.09% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Alpha DNA Investment Management's EVH Position: Q2 2024 in Review

Alpha DNA Investment Management sold out of Evolent Health (EVH) in Q2 2024, closing a stake of 16,057 shares — an estimated $527K sold.

Alpha DNA Investment Management first reported a position in EVH in Q4 2020 and held it in 5 quarters. The position peaked at $1.58M in Q4 2021. 243 funds tracked by Wall St. Rank hold EVH as of Q2 2024.

Alpha DNA Investment Management reported no remaining Evolent Health position as of Q2 2024 after selling out during the quarter.
Alpha DNA Investment Management sold 16,057 Evolent Health shares in Q2 2024, an estimated $527K.
Alpha DNA Investment Management first reported a position in Evolent Health in Q4 2020 and held it in 5 quarters.
Alpha DNA Investment Management's Evolent Health position peaked at $1.58M in Q4 2021.
243 funds tracked by Wall St. Rank held Evolent Health as of Q2 2024.

Based on Alpha DNA Investment Management's 13F filing for Q2 2024, filed 14 Aug 2024.